[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443803":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":71,"collaborators":10,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":10,"studyType":88,"phases":10,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Ludwig-Maximilians - University of Munich","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Alzheimer's Disease",null,"Patients with a Alzheimer's Disease diagnosis",[13],"Radiation: positron emission tomography (PET)",{"label":15,"type":10,"description":16,"interventionNames":17},"Mild Cognitive Impairment","Patients with a mild cognitive impairment diagnosis",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Subjective Cognitive Decline","Patients with a subjective cognitive decline diagnosis",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"RADIATION","positron emission tomography (PET)","18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.",[9,15,19],[29],{"name":30,"affiliation":31,"role":32},"Robert Perneczky, Prof.Dr.med.","Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+4989440055863","PSY.Alzheimerzentrum@med.uni-muenchen.de",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Lena Burow, M.Sc.","+4989440055898","lena.burow@med.uni-muenchen.de",[43],{"facility":31,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","München","Bavaria","80336","Germany","DE",{"type":51,"coordinates":52},"Point",[53,54],13.46314,48.69668,{"lat":54,"lon":53},[57,60,62,65,67,69],{"name":58,"role":35,"phone":59,"phoneExt":10,"email":37},"Robert Perneczky, Prof. Dr.","+49 89 4400 55863",{"name":39,"role":35,"phone":61,"phoneExt":10,"email":41},"+49 89 4400 55898",{"name":63,"role":64,"phone":10,"phoneExt":10,"email":10},"Carolin Kurz, Dr.med.","SUB_INVESTIGATOR",{"name":66,"role":64,"phone":10,"phoneExt":10,"email":10},"Boris-Stephan Rauchmann, Dr. med.",{"name":68,"role":64,"phone":10,"phoneExt":10,"email":10},"Selim Gürsel",{"name":70,"role":64,"phone":10,"phoneExt":10,"email":10},"Matthias Brendel, PD Dr. med.",{"type":32,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Robert Perneczky","Principal Investigator","100443803","amyloid--clearance-mechanisms-in-alzheimers-disease-100443803",false,"NCT05059158","Amyloid-β Clearance Mechanisms in Alzheimer's Disease","Amyloid-β Clearance Mechanisms: A Multi-modal Study on Lymphatic, Glymphatic and Blood-brain-barrier Function in Alzheimer's Disease","AmyClearAD","Inclusion Criteria:\n\n* Diagnosis of amnestic MCI or AD dementia or clinical normal\n* Able to provide written informed consent\n* Unchanged pharmacotherapy within 4 days prior to the study specific assessments\n* Fluent in German\n\nExclusion Criteria:\n\n* Unable to give informed consent or has a legal guardian\n* Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder\n* Clinically relevant depression\n* Acute suicidality\n* Current alcohol, drug or medication abuse\n* History of severe traumatic brain injury within 3 months prior to inclusion\n* Structural lesions of the basal ganglia or brain stem\n* Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus\n* Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension\n* Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication\n* Renal failure \\> stage 3 (GFR \\\u003C 30 mL\u002Fmin)\n* Pregnancy\n* Unresolved malignancies within two years prior to inclusion\n* Severe current infections or other chronic or systemic disorders\n* Other circumstances which preclude participation based on the investigator's judgement","ALL","50 Years","85 Years",{"count":86,"type":87},60,"ESTIMATED","OBSERVATIONAL","The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.",[91],"Alzheimer's Disease (AD)",[9,15,93,94,95,96],"Sleep","Actigraphy","Blood-brain-barrier","Amyloid-β Clearance Mechanisms","2025-07-01",{"date":99,"type":100},"2025-07-04","ACTUAL",{"date":102,"type":100},"2021-06-01",{"date":104,"type":87},"2025-10",{"name":5,"class":6},1]